

T-CELL PROLIFERATION AND ACTIVATION
T-HELPER CELL ACTIVATION AND ANTIBODY PRODUCTION
MACROPHAGE PHAGOCYTOSIS
+ACTIVATION
-INHIBITION
β2-MICRO-GLOBULIN (HLA-I)
C2TA (HLA-II)
CD47

FIG. 1A



Uterine Vessels
Maternal Side
Fetal Side
Syncytiotrophoblast
Cytotrophoblast
Umbilical Vessels

FIG. 1B



SPLENOCYTES
SYNCYTIOTROPHOBLAST
MHC-I
MHC-II
CD47
GAPDH

FIG. 1C



MIPSCS
MURINE FIBROBLASTS
NANOG
OCT 4
SOX 2
ESRRB
TBX3
TCL1
ACTIN
NEG. CONTROL

FIG. 2



2X10^6 IPS CELLS (C57BL/6)I.M.
TERATOMA DEVELOPMENT IN %
100
80
60
40
20
0
C56BL/6 (SYNGENEIC)
N=10
BALB/c (ALLOGENEIC)
N=10
BALB/c NUDE (T-CELL DEF)
N=5
SCID BEIGE (NEG CTRL)
N=8

FIG. 3




FIG. 4



MHCII
FOLD CHANGE
0
1
2
3
4
5
6
N.S.
TNF ALPHA
IPSCS DOUBLE KO
1.0 FOLD
IPSCS DOUBLE KO TNFA
1.0 FOLD
COUNT
MHC II
ISOTYPE
MHC II
N=2, IN TRIPLICATES
UNABHÄNGIGER T-TEST †
= P<0.01

FIG. 5



FOLD CHANGE
6
4
2
0
MHC-I
MHC-II
CD47
MIPSC
MIPSC^HYPO
MIPSC
MIPSC^HYPO
MIPSC
MIPSC^HYPO

FIG. 6A



TERATOMA VOLUME IN mm3
2000
1500
1000
500
0
0 3 7 11 15 19 23 27 31 35 39 43 47
C57BL/6
SYNGENEIC
BALB/C
ALLOGENEIC
IPSC^HYPO
BALB/C
ALLOGENEIC IPSC
DAYS

FIG. 6B




FIG. 7




FIG. 8B




FIG. 8A




FIG. 9C




FIG. 9B




FIG. 9A




FIG. 10A




FIG. 10B




FIG. 10C




FIG. 10D




FIG. 10E




FIG. 11A




FIG. 11B





FIG. 11C






FIG. 11D

FIG. 11E




FIG. 12C





FIG. 12B






FIG. 12D

FIG. 12E




FIG. 12A




FIG. 13C




FIG. 13B




FIG. 13D




FIG. 13E




FIG. 13A




FIG. 14A

FIG. 14B




FIG. 14C




FIG. 15A




FIG. 15B




FIG. 16




FIG. 17C




FIG. 17B




FIG. 17A




FIG. 18C




FIG. 18B




FIG. 18A




FIG. 19B




FIG. 19A




FIG. 20B




FIG. 20A




FIG. 21A

FIG. 21B




FIG. 21C




FIG. 22A




FIG. 22C




FIG. 22B




FIG. 23A




FIG. 23B

FIG. 23C




FIG. 24A




FIG. 24C




FIG. 24B




VS.
MIEC
**
NK FUSION PROTEIN (FOLD)
0
2
4
6
FROM WT
FROM B2M-/- C2TA-/- CD47 TG
VS.
MISMC
NK FUSION PROTEIN (FOLD)
0
2
4
6
FROM WT
FROM B2M-/- C2TA-/- CD47 TG
VS.
MICM
NK FUSION PROTEIN (FOLD)
0
2
4
6
FROM WT
FROM B2M-/- C2TA-/- CD47 TG
YAK-1
NK FUSION PROTEIN (FOLD)
0
2
4
6

FIG. 25







FIG. 26B






FIG. 26A




FIG. 27




FIG. 28

PCR FOR PLURIPOTENCY GENES:




FIG. 29




FIG. 30B




FIG. 30A




FIG. 31D




FIG. 31B




FIG. 31C




FIG. 31A




FIG. 32A




FIG. 32B




FIG. 33A

FIG. 33B



FIG. 34




FIG. 34C




FIG. 34B




FIG. 34A




FIG. 35B




FIG. 35C




FIG. 35A




FIG. 36C




FIG. 36B




FIG. 36A




FIG. 37A

FIG. 37B